CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.

Trial Details

NCT ID
NCT05054257
Phase
PHASE1
Sponsor
Institute of Hematology and Blood Transfusion, Czech Republic
Status
RECRUITING
Cancer Type
Burkitt Lymphoma Lymphoma
Interventions
  • Autologous CAR19 T lymphocytes
Locations (sample)
  • Prague, Czechia|50.08804,14.42076

Key Eligibility Criteria

  • Patient with refractory or relapsing CD19 positive B-ALL or B-NHL defined as:
  • B-ALL refractory to treatment or in the second or subsequent relapse (hematological OR molecular), OR
  • B-NHL refractory to treatment or in first relapse ineligible for autologous stem cell transplantation (ASCT) or in second to fourth relapse, OR
  • B-ALL or B-NHL relapsing after autologous or allogeneic hematopoietic cell transplantation (HCT).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Burkitt Lymphoma Lymphoma Trials on Trialify →